Idogen AB (publ) at its Annual General Meeting to be held on 12 May 2020, proposed the election of Sharon Longhurst to succeed Karin Hoogendoorn, who has declined re-election as Director. Karin Hoogendoorn has declined re-election after having started in a new position as Head of Global Preclinical Services Cell and Gene Therapy Products at Lonza.